{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:56:00Z","timestamp":1777859760089,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Amantadine is commonly used to treat Parkinson\u2019s disease. A case of myoclonus and asterixis was associated with amantadine is reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary:<\/jats:title>\n                    <jats:p>An 80-year-old man with Parkinson\u2019s disease diagnosed in 2015 was started on amantadine for treatment of progressive tremor and orofacial dyskinesias induced by levodopa. He took amantadine 100mg orally daily for 7 days, then increased to 100mg twice a day thereafter. The patient complained of \u201cworsening tremor\u201d after 9 days and amantadine was decreased to 100mg daily. After 1 month on this dose, the patient reported that his \u201ctremor\u201d persisted and experienced visual hallucinations. His examination demonstrated diffuse myoclonus throughout his extremities and trunk, as well as asterixis when attempting to stand or holding his arms antigravity. Laboratory testing for renal and hepatic failure was unrevealing. Amantadine was reduced to 50mg daily for 4 days and then discontinued. Myoclonus resolved 3 days after discontinuation of amantadine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While amantadine-induced myoclonus is rare, health care providers should be vigilant in monitoring for signs and symptoms of myoclonus following amantadine initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190021997003","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T04:42:16Z","timestamp":1614141736000},"page":"814-817","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Amantadine Associated Myoclonus: Case Report and Review of the Literature"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-3238","authenticated-orcid":false,"given":"Linda H.","family":"Poon","sequence":"first","affiliation":[{"name":"San Francisco Veterans Affairs Health Care System, CA, USA"},{"name":"Pharmacy, University of California San Francisco School of Pharmacy, CA, USA"},{"name":"Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey J.","family":"Lee","sequence":"additional","affiliation":[{"name":"San Francisco Veterans Affairs Health Care System, CA, USA"},{"name":"Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Vuong","sequence":"additional","affiliation":[{"name":"University of California San Francisco, CA, USA"},{"name":"Parkinson\u2019s Disease, Research, Education and Clinical Center, San Francisco Veterans Affairs Health Care System, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Rafael","family":"Zuzuarregui","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease, Research, Education and Clinical Center, San Francisco Veterans Affairs Health Care System, CA, USA"},{"name":"Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"bibr1-0897190021997003","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418020-00003"},{"key":"bibr2-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8357-z"},{"key":"bibr3-0897190021997003","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.364"},{"key":"bibr4-0897190021997003","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.180572"},{"key":"bibr5-0897190021997003","volume-title":"Symmetrel (amantadine hydrochloride) [package insert]","year":"2009"},{"key":"bibr6-0897190021997003","volume-title":"Gocovri (amantadine) extended release [package insert","year":"2017"},{"key":"bibr7-0897190021997003","volume-title":"Osmolex ER (amantadine) extended-release [package insert","year":"2020"},{"key":"bibr8-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-013-0216-3"},{"key":"bibr9-0897190021997003","first-page":"23","volume-title":"Myoclonus and Paroxysmal Dyskinesias. Advances in Neurology","volume":"89","author":"Caviness JN","year":"2002"},{"key":"bibr10-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2793-5"},{"issue":"4","key":"bibr11-0897190021997003","first-page":"1055","volume":"25","author":"Caviness JN","year":"2019","journal-title":"Continuum"},{"key":"bibr12-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490470075011"},{"key":"bibr13-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.2.279"},{"key":"bibr14-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs043"},{"key":"bibr15-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110123"},{"key":"bibr16-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23140"},{"key":"bibr17-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr18-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199212000-00014"},{"key":"bibr19-0897190021997003","volume-title":"Wellbutrin (Bupropion Hydrochloride) [package insert]","year":"2019"},{"key":"bibr20-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2018.09.019"},{"key":"bibr21-0897190021997003","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200503000-00011"},{"key":"bibr22-0897190021997003","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5359.44024"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190021997003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190021997003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190021997003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:09Z","timestamp":1777509429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190021997003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/0897190021997003"],"URL":"https:\/\/doi.org\/10.1177\/0897190021997003","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]}}}